A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities - Concepedia

Concepedia

Publication | Open Access

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities

DOI Full Paper Access

64

Citations

20

References

2015

Year

Rick L. Haas, Hans Gelderblom, Stefan Sleijfer, Hester H. van Boven, Astrid N. Scholten, L. Dewit, Gerben R. Borst, Jos A. van der Hage, J. Martijn Kerst, Remi A. Nout,

Acta Oncologica

Abstract

Apart from hepatotoxicity, neoadjuvant pazopanib 800 mg daily in combination with 50 Gy seems tolerable; the regimen appears to demonstrate promising activity in ESTS and is the recommended dose for further studies.

References

	Year	Citations

Page 1